Latest in Research & Development

AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic

The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies

Find out more

You need to be a subscriber to read this article.
Click here to find out more.

EU AI Act: five things you need to know

The EU AI Act brings several important changes for organisations. According to Nina Wamsbach, Senior Communications Manager at Scheer Group, here’s what you should be aware of
See more

Baseline Therapuetics launches to advance GLP-1 Phase III Programme in Alcohol Use Disorder

The clinical-stage biotech has launched to progress BT-001, a once-weekly GLP-1 receptor agonist, into FDA-aligned Phase III trials for alcohol use disorder, with studies planned to begin in 2026

Researchers identify early signs of Parkinson's in the blood

Researchers at Chalmers University of Technology have identified early-stage Parkinson’s disease biomarkers detectable in blood, revealing a limited diagnostic window that could enable screening and earlier intervention years before motor symptoms appear

iXCells and Rosebud Biosciences pair up to advance organoid-based models for rare diseases

The expansion of iXCells’ iPSCore platform with integration of 3D human organoid expertise will enable evaluation of drug toxicity and tissue-specific responses, meeting growing demand for scalable, patient-relevant human models to support translational decision-making in drug development

BioMed X partners with the Government of Barbados to advance early diabetic kidney disease therapy

The new project, supported by the European Union’s PharmaNext Programme, focuses on population-specific molecular profiling and AI-driven precision medicine for patients of African descent

Ellipses in-licenses first-in-class B7H3 antibody drug conjugate from China

Ellipses Pharma has entered into a collaboration and licence agreement with Innolake Biopharm Co. Ltd to develop a clinical-stage first-in-class antibody drug conjugate (ADC)

MetP Pharma unveils brain-targeted intranasal GLP-1 delivery technology

Preclinical data shows the company's proprietary nose-to-brain technology enables rapid, dose-dependent brain targeting of intranasal semaglutide with low systemic exposure, opening new opportunities for CNS-focused GLP-1 therapies

EMBO Installation Grant supports new genome editing lab at Vilnius University

Dr C. Patinios Awarded EMBO Installation Grant to advance genome editing research in Lithuania

Drug-loaded pellets: unlocking flexible oral dosage design with modern pelletisation technologies

Produced using advanced extrusion–spheronisation technologies such as GEA’s NICA systems, drug-loaded pellets are gaining traction as a flexible and scalable oral solid dosage platform that enhances release control, patient outcomes and manufacturing efficiency

Latest posts in Research & Development

Merck and Moderna announce 5-year data for intismeran autogene in combination with KEYTRUDA

Eight Phase II and Phase III clinical trials are under way across multiple tumour types, including melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma

FDA and EMA issue guiding principles for AI in drug development

The set of ten principles gives broad guidance on AI use in evidence generation and monitoring across all phases of a medicine, from early research and clinical trials to manufacturing and safety monitoring

Bio-Sourcing and Zerion Pharma secure Eurostars funding to develop HER2 oral monoclonal antibody

The pair have been awarded a €1.3m Eurostars grant to develop an oral formulation of the anti-HER2 monoclonal antibody trastuzumab for breast cancer, combining Bio-Sourcing’s BioMilk platform with Zerion’s Dispersome technology to advance the candidate through preclinical development

FairJourney Bio launches cryo-EM services to support antibody discovery and biologics design

The new offering at the company's San Diego laboratories provides high-resolution structural insights to accelerate antibody discovery, selection and optimisation across the biologics R&D pipeline

Studies on HIV and TB reveal tradeoffs for both viruses and immune system in race to survive

Research teams have identified mechanisms by which HIV can evade lenacapavir, at the cost of the virus's reproduction and how the immune system can use bacteria to protect against infection — until TB evolved to take advantage

Enara Bio expands Boehringer Ingelheim partnership as DARKFOX programme moves toward the clinic

Enara Bio has entered 2026 with renewed momentum after Boehringer Ingelheim licensed additional Dark Antigen targets under their oncology collaboration. The company is also continuing to expand its EDAPT discovery platform

Early stage clinical trials highlight the convergence of novel therapeutics and enabling technologies

Early stage clinical development is increasingly being shaped by advances in drug discovery and the technologies and manufacturing strategies that enable the safe, precise and scalable delivery of new therapies

Breast cancer is the world’s most studied disease for fifth consecutive year according to analysis from Phesi

The US led global clinical trial activity in 2025 and across all top five indications, with China recording the fastest growth in the number of recruiting clinical trial sites

One in ten Britons are using or interested in using GLP-1s for weight loss, according to new research

GLP-1 use and interest was more prevalent among women, as well as those who reported difficulties with their finances or who had experienced psychological distress within the previous month

Eli Lilly pays $55m for obesity drug research collab with Nimbus Therapeutics

The pair have entered into a multi-year research collaboration to develop a novel oral treatment for obesity and other metabolic diseases

LoQus23 Therapeutics nominates new oral drug candidate for Huntington's Disease

The biotech company has put forward LQT-23, a potent, highly differentiated, first-in-class allosteric small molecule inhibitor of MSH3/MutSβ with a unique mechanism of action with potential to slow or stop the progression of HD

Sponsor content

PSI launches platform to speed up site ID, startup and enrolment in pivotal studies

SYNETIC is designed to speed up site identification, startup and patient enrollment in pivotal clinical trials

Piramal Pharma Solutions introduces tablet-in-capsule capabilities

Enhancing dosing flexibility and patient-centric drug delivery

Biosero launches GoSimple™, a standardised automation-ready workcell

GoSimple workcells simplify workflows and enhance lab efficiency with selected Sartorius and BD instruments

Cellistic launches new iPSC-based GMP platforms to boost cell therapy development

Echo-T, Echo-Cardio, and Echo-Endothelial enable scalable immuno-oncology and regenerative therapies

Titan Enterprises highly commended for Manufacturer of the Year at industry awards

Recognition reflects the company’s investment in innovation and precision flow measurement

Free online course introduces fundamentals of SFC

Learn how SFC can improve efficiency and reduce environmental impact

Thermo Fisher launches general purpose centrifuges with natural refrigerant cooling

New X and S Series models offer high performance with reduced environmental impact

Work safely with hazardous substances – new Asecos catalogue available now

Asecos cabinets help minimise risks when storing flammable substances

Redefining QP training for today’s professionals

How NSF is making specialist learning more flexible and accessible

NSF’s QP training program combines technical skill with personalised guidance

A mentoring-led approach supporting delegates through every stage of the QP journey

SU Puresonic ultrasonic sensor ensures precise hygienic flow measurement

Innovative design meets the highest standards in food, pharma, and water treatment

Abzena advances ADC development with ThioBridge conjugation technology

Next-generation conjugation delivers greater stability, potency and control for targeted cancer therapeutics

Featured companies

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO), offering end-to-end development and manufacturing solutions across the drug life... Quotient Sciences is a drug development and manufacturing accelerator providing integrated services across the entire development pathway for small-molecule and peptide drug... PCI Pharma Services: Your bridge between life-changing therapies and patients. CARBOGEN AMCIS is a global Contract Development and Manufacturing Organization (CDMO) providing drug development and commercialization services to the pharmaceutical and...
See more